Implication of hepatokines in metabolic disorders and cardiovascular diseases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Tae Woo | - |
dc.contributor.author | Yoo, Hye Jin | - |
dc.contributor.author | Choi, Kyung Mook | - |
dc.date.accessioned | 2021-09-03T23:10:30Z | - |
dc.date.available | 2021-09-03T23:10:30Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 2214-6474 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88407 | - |
dc.description.abstract | The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases. (C) 2016 The Authors. Published by Elsevier B.V. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | GROWTH-FACTOR 21 | - |
dc.subject | ANGIOPOIETIN-LIKE 4 | - |
dc.subject | SERUM FGF21 LEVELS | - |
dc.subject | PLASMA FETUIN-A | - |
dc.subject | FATTY LIVER-DISEASE | - |
dc.subject | INSULIN-RESISTANCE | - |
dc.subject | SELENOPROTEIN P | - |
dc.subject | HEPATIC STEATOSIS | - |
dc.subject | MYOCARDIAL-INFARCTION | - |
dc.subject | DIABETES-MELLITUS | - |
dc.title | Implication of hepatokines in metabolic disorders and cardiovascular diseases | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Kyung Mook | - |
dc.identifier.doi | 10.1016/j.bbacli.2016.03.002 | - |
dc.identifier.scopusid | 2-s2.0-84960908819 | - |
dc.identifier.wosid | 000386869500013 | - |
dc.identifier.bibliographicCitation | BBA CLINICAL, v.5, pp.108 - 113 | - |
dc.relation.isPartOf | BBA CLINICAL | - |
dc.citation.title | BBA CLINICAL | - |
dc.citation.volume | 5 | - |
dc.citation.startPage | 108 | - |
dc.citation.endPage | 113 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | GROWTH-FACTOR 21 | - |
dc.subject.keywordPlus | ANGIOPOIETIN-LIKE 4 | - |
dc.subject.keywordPlus | SERUM FGF21 LEVELS | - |
dc.subject.keywordPlus | PLASMA FETUIN-A | - |
dc.subject.keywordPlus | FATTY LIVER-DISEASE | - |
dc.subject.keywordPlus | INSULIN-RESISTANCE | - |
dc.subject.keywordPlus | SELENOPROTEIN P | - |
dc.subject.keywordPlus | HEPATIC STEATOSIS | - |
dc.subject.keywordPlus | MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | DIABETES-MELLITUS | - |
dc.subject.keywordAuthor | Hepatokine | - |
dc.subject.keywordAuthor | Fetuin-A | - |
dc.subject.keywordAuthor | Fibroblast growth factor 21 | - |
dc.subject.keywordAuthor | Selenoprotein P | - |
dc.subject.keywordAuthor | Angiopoietin-like protein 4 | - |
dc.subject.keywordAuthor | Leukocyte cell-derived chemotaxin 2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.